- Search History will be lost after eight hours of inactivity.
- Search numbers may not be continuous; all searches are represented.
- To save search indefinitely, click query # and select Save in My NCBI.
- To combine searches use #search, e.g., #2 AND #3 or click query # for more options.

Search	Most Recent Queries	Time	Result
#14	Search **epha2 and antigen and CTL**	14:04:06	1
#13	Search **epha2 and peptide and immunogenic**	14:04:00	1
#24	Search **ephrinA2 and peptide**	14:03:21	4
#23	Search **ephrin and peptide**	14:03:09	778
#22	Search **ephrin and epitope**	14:02:33	4
#21	Search **epa2**	14:02:08	1
#19	Search **eck and epitope**	13:58:41	4
#18	Search **epha2 and epitope**	13:57:55	6
#16	Search **epha2 and CTL**	13:54:54	2
#12	Search **epha2 and peptide**	13:47:13	80
#11	Search **epha2**	13:47:03	155
#10	Search **#5 and CD8**	13:46:24	1
#7	Search **epha and peptide and t cell**	13:42:41	5
#6	Search **epha and peptide and epitope**	13:42:06	1
#5	Search **epha and peptide**	13:41:43	76
#4	Search **epha and immunogenic peptide**	13:41:37	0
#3	Search **epha**	13:41:22	118
#2	Search **epha and MHC 1**	13:41:16	0
#1	Search **epha and t epitope**	13:41:09	0

Clear History

WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Friday, October 06, 2006

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ		
☐	L12	L11 and CTL	5
☐	L11	L8 and (immunogenic peptide)	13
☐	L10	L9 and CTL	29
☐	L9	L8 and peptide	124
☐	L8	ephrinA2 or epha2 and epitope	131
☐	L7	L6 and immunogen	16
☐	L6	L5 and epitope	35
☐	L5	L4 and CTL	37
☐	L4	L3 and HLA	237
☐	L3	L1 and peptide	1274
☐	L2	L1 and peptide or epitope	66196
☐	L1	ephrinA2 or epha2 or eck	10572

END OF SEARCH HISTORY

```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTALAB1643

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  FEB 27  New STN AnaVist pricing effective March 1, 2006
 NEWS  4  MAY 10  CA/CAplus enhanced with 1900-1906 U.S. patent records
 NEWS  5  MAY 11  KOREAPAT updates resume
 NEWS  6  MAY 19  Derwent World Patents Index to be reloaded and enhanced
 NEWS  7  MAY 30  IPC 8 Rolled-up Core codes added to CA/CAplus and
                  USPATFULL/USPAT2
 NEWS  8  MAY 30  The F-Term thesaurus is now available in CA/CAplus
 NEWS  9  JUN 02  The first reclassification of IPC codes now complete in
                  INPADOC
 NEWS 10  JUN 26  TULSA/TULSA2 reloaded and enhanced with new search and
                  and display fields
 NEWS 11  JUN 28  Price changes in full-text patent databases EPFULL and PCTFULL
 NEWS 12  JUl 11  CHEMSAFE reloaded and enhanced
 NEWS 13  JUl 14  FSTA enhanced with Japanese patents
 NEWS 14  JUl 19  Coverage of Research Disclosure reinstated in DWPI
 NEWS 15  AUG 09  INSPEC enhanced with 1898-1968 archive
 NEWS 16  AUG 28  ADISCTI Reloaded and Enhanced
 NEWS 17  AUG 30  CA(SM)/CAplus(SM) Austrian patent law changes
 NEWS 18  SEP 11  CA/CAplus enhanced with more pre-1907 records
 NEWS 19  SEP 21  CA/CAplus fields enhanced with simultaneous left and right
                  truncation
 NEWS 20  SEP 25  CA(SM)/CAplus(SM) display of CA Lexicon enhanced
 NEWS 21  SEP 25  CAS REGISTRY(SM) no longer includes Concord 3D coordinates
 NEWS 22  SEP 25  CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
 NEWS 23  SEP 28  CEABA-VTB classification code fields reloaded with new
                  classification scheme

 NEWS EXPRESS  JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *
```

```
FILE 'HOME' ENTERED AT 15:00:16 ON 06 OCT 2006

=> file caplus, bioeng, biotechno, biotechds, esbiobase
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'CAPLUS' ENTERED AT 15:00:56 ON 06 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOENG' ENTERED AT 15:00:56 ON 06 OCT 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHNO' ENTERED AT 15:00:56 ON 06 OCT 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOTECHDS' ENTERED AT 15:00:56 ON 06 OCT 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'ESBIOBASE' ENTERED AT 15:00:56 ON 06 OCT 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

=> s (t cell epitope) or (T epitope)
   3 FILES SEARCHED...
L1         9390 (T CELL EPITOPE) OR (T EPITOPE)

=> s epha2 and L1
L2            5 EPHA2 AND L1

=> duplicate remove l2
DUPLICATE PREFERENCE IS 'CAPLUS, BIOTECHDS'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L2
L3             4 DUPLICATE REMOVE L2 (1 DUPLICATE REMOVED)

=> d l3 bib abs 1-4

L3   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2006:333546  CAPLUS
DN   144:329777
TI   Epitope variants for enhancing glioma-specific cytotoxic T cell response
IN   Storkus, Walter J.; Sato, Hidemitsu; Okada, Hideho; Eguchi, Junichi
PA   University of Pittsburgh of the Commonwealth System of Higher Education,
     USA
SO   PCT Int. Appl., 37 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2006034334         A2    20060330    WO 2005-US33794         20050921
     WO 2006034334         A3    20060914
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
             NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
             SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
             YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
```

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2004-611797P P 20040921

AB The authors disclose peptide variants derived from the interleukin-13 receptor α2, which exhibit increased affinity for HLA-A2 and elicit an enhanced cytotoxic T lymphocyte (CTL) response. The peptide variants can be used as a vaccine for glioma and can be formulated into compns. for medical or veterinary use. In addition, the authors also disclose a peptide derived from the EphA2 tyrosine kinase receptor which may be used for therapy of glioma.

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:120967 CAPLUS

DN 142:217364

TI Human EphA2 protein T cell epitope agonists for ELISPOT assay and as vaccines against tumor overexpressing EphA2

IN Storkus, Walter J.; Kinch, Michael S.

PA University of Pittsburgh-of the Commonwealth System of Higher Education, USA; Medimmune, Inc.

SO PCT Int. Appl., 115 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012350	A2	20050210	WO 2004-US23931	20040722
	WO 2005012350	A3	20050714		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004261603	A1	20050210	AU 2004-261603	20040722
	CA 2533789	AA	20050210	CA 2004-2533789	20040722
	US 2005048550	A1	20050303	US 2004-897711	20040722
	EP 1651671	A2	20060503	EP 2004-779136	20040722
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	US 2006019899	A1	20060126	US 2005-233796	20050923
PRAI	US 2003-491046P	P	20030730		
	US 2004-897711	A1	20040722		
	WO 2004-US23931	W	20040722		

AB EphA2 T-cell epitope agonists are provided herein. The agonists include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivs. thereof. The EphA2 T-cell epitope agonists are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The agonists also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma. The EphA2 agonists also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:385550 CAPLUS
DN 142:428349
TI Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors
AU Hatano, Manabu; Kuwashima, Naruo; Tatsumi, Tomohide; Dusak, Jill E.; Nishimura, Fumihiko; Reilly, Karlyne M.; Storkus, Walter J.; Okada, Hideho
CS Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA
SO Journal of Translational Medicine (2004), 2, No pp. given
CODEN: JTMOBV; ISSN: 1479-5876
URL: http://www.translational-medicine.com/content/pdf/1479-5876-2-40.pdf
PB BioMed Central Ltd.
DT Journal; (online computer file)
LA English
AB Background: A novel tyrosine kinase receptor EphA2 is expressed at high levels in advanced and metastatic cancers. The authors examined whether vaccinations with synthetic mouse EphA2 (mEphA2)-derived peptides that serve as T cell epitopes could induce protective and therapeutic anti-tumor immunity. Methods: C57BL/6 mice received s.c. vaccinations with bone marrow-derived dendritic cells (DCs) pulsed with synthetic peptides recognized by CD8+ (mEphA2671-679, mEphA2682-689) and CD4+ (mEphA230-44) T cells. Splenocytes (SPCs) were harvested from primed mice to assess the induction of cytotoxic T lymphocyte (CTL) responses against syngeneic glioma, sarcoma and melanoma cell lines. The ability of these vaccines to prevent or treat tumor (s.c. injected MCA205 sarcoma or B16 melanoma; i.v. injected B16-BL6) establishment/progression was then assessed. Results: Immunization of C57BL/6 mice with mEphA2-derived peptides induced specific CTL responses in SPCs. Vaccination with mEPhA2 peptides, but not control ovalbumin (OVA) peptides, prevented the establishment or prevented the growth of EphA2+ or EphA2-neg. syngeneic tumors in both s.c. and lung metastasis models. Conclusions: These data indicate that mEphA2 can serve as an attractive target against which to direct anti-tumor immunity. The ability of mEphA2 vaccines to impact EphA2-neg. tumors such as the B16 melanoma may suggest that such beneficial immunity may be directed against alternative EphA2+ target cells, such as the tumor-associated vascular endothelial cells.
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1
AN 2003:837593 CAPLUS
DN 139:322275
TI Peptide T epitopes of the EphA2 antigen for antitumor immunotherapy
IN Kosmatopoulos, Kostas; Alves, Pedro
PA Institut National de la Sante et de la Recherche Medicale INSERM, Fr.; Institut Gustave Roussy
SO Fr. Demande, 22 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2838742	A1	20031024	FR 2002-5048	20020423
	FR 2838742	B1	20040709		
	CA 2482930	AA	20031106	CA 2003-2482930	20030423
	WO 2003091383	A2	20031106	WO 2003-FR1280	20030423
	WO 2003091383	A3	20040401		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

```
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
            PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
            TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    AU 2003262810        A1    20031110    AU 2003-262810         20030423
    EP 1497417           A2    20050119    EP 2003-740654         20030423
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    US 2006034856        A1    20060216    US 2005-511273         20050627
PRAI FR 2002-5048        A     20020423
    WO 2003-FR1280       W     20030423
AB  The invention discloses peptides constituting EphA2 antigen
    T epitopes, presented by MHC I.  The peptides are useful
    in particular for antitumor immunotherapy.
RE.CNT  4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s (epha2 or ephrin) and peptide and immunogen
L4            0 (EPHA2 OR EPHRIN) AND PEPTIDE AND IMMUNOGEN

=> s epha2 and peptide
L5           46 EPHA2 AND PEPTIDE

=> duplicate remove l5
DUPLICATE PREFERENCE IS 'CAPLUS, BIOTECHNO, BIOTECHDS, ESBIOBASE'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L5
L6            31 DUPLICATE REMOVE L5 (15 DUPLICATES REMOVED)

=> s HLA and L6
L7            9 HLA AND L6

=> duplicate remove L7
PROCESSING COMPLETED FOR L7
L8             9 DUPLICATE REMOVE L7 (0 DUPLICATES REMOVED)

=> d l8 bib abs 1-9

L8   ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2006:333546  CAPLUS
DN   144:329777
TI   Epitope variants for enhancing glioma-specific cytotoxic T cell response
IN   Storkus, Walter J.; Sato, Hidemitsu; Okada, Hideho; Eguchi, Junichi
PA   University of Pittsburgh of the Commonwealth System of Higher Education,
     USA
SO   PCT Int. Appl., 37 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2006034334         A2    20060330    WO 2005-US33794         20050921
     WO 2006034334         A3    20060914
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
```

NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

PRAI US 2004-611797P P 20040921

AB The authors disclose peptide variants derived from the interleukin-13 receptor α2, which exhibit increased affinity for HLA-A2 and elicit an enhanced cytotoxic T lymphocyte (CTL) response. The peptide variants can be used as a vaccine for glioma and can be formulated into compns. for medical or veterinary use. In addition, the authors also disclose a peptide derived from the EphA2 tyrosine kinase receptor which may be used for therapy of glioma.

L8 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:120967 CAPLUS
DN 142:217364
TI Human EphA2 protein T cell epitope agonists for ELISPOT assay and as vaccines against tumor overexpressing EphA2
IN Storkus, Walter J.; Kinch, Michael S.
PA University of Pittsburgh-of the Commonwealth System of Higher Education, USA; Medimmune, Inc.
SO PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012350	A2	20050210	WO 2004-US23931	20040722
	WO 2005012350	A3	20050714		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004261603	A1	20050210	AU 2004-261603	20040722
	CA 2533789	AA	20050210	CA 2004-2533789	20040722
	US 2005048550	A1	20050303	US 2004-897711	20040722
	EP 1651671	A2	20060503	EP 2004-779136	20040722
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	US 2006019899	A1	20060126	US 2005-233796	20050923
PRAI	US 2003-491046P	P	20030730		
	US 2004-897711	A1	20040722		
	WO 2004-US23931	W	20040722		

AB EphA2 T-cell epitope agonists are provided herein. The agonists include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivs. thereof. The EphA2 T-cell epitope agonists are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The agonists also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a

treatment for cancers that overexpress EphA2, such as renal cell carcinoma. The EphA2 agonists also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.

L8 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1020555 CAPLUS
DN 143:320266
TI Genes with differential expression profile between human dental pulp stem cells and mesenchymal stem cells and use for regenerating tooth germ
IN Ueda, Minoru; Yamada, Yoichi
PA Hitachi Medical Corp., Japan
SO Jpn. Kokai Tokkyo Koho, 246 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2005253442	A2	20050922	JP 2004-111582	20040309
PRAI	JP 2004-111582		20040309		

AB The present invention relates to a group of genes whose expression profile are different between human dental pulp stem cells and mesenchymal stem cells, as well as a method for regenerating tooth germ using these genes. According to the present invention, the gene expression profiles and cluster anal. between human dental pulp stem cells (hDPSCs) and mesenchymal stem cells (hMSCs) as representative populations of odontoprogenitor and osteoprogenitor cell were revealed, and a group of genes whose expression profile are different between human dental pulp stem cells and mesenchymal stem cells was identified. By utilizing the groups of the genes of the present invention together with the dental pulp stem cells and mesenchymal stem cells, hard tissue such as tooth germ, dental pulp, dentin or bone can be regenerated. The present inventors investigated the gene expression profiles and cluster anal. between human dental pulp stem cells (hDPSCs) and mesenchymal stem cells (hMSCs) as representative populations of odontoprogenitor and osteoprogenitor cells, resp. At first, the present inventors confirmed the differential expression of Alkaline phosphatase (ALP) activity, Dentin matrix protein 1 (DMP 1), Dentin phosphosialoprotein (DSPP) using by real time reverse-transcriptase polymerase chain reaction (RT-PCR) in total RNA from primary cultures. The number of genes in hDPSCs(I) that were up-regulated by 2>-fold, compared to hMSCs, was 614 (Table, IV). On the other band, the number of genes down regulated by <2-fold in hDPSCs (I) was 296 (Table III, IV).

L8 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1201395 CAPLUS
DN 144:189389
TI EphA2 as a glioma-associated antigen: A novel target for glioma vaccines
AU Hatano, Manabu; Eguchi, Junichi; Tatsumi, Tomohide; Kuwashima, Naruo; Dusak, Jill E.; Kinch, Michel S.; Pollack, Ian F.; Hamilton, Ronald L.; Storkus, Walter J.; Okada, Hideho
CS Department of Neurological Surgery, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA
SO Neoplasia (Ann Arbor, MI, United States) (2005), 7(8), 717-722
CODEN: NEOPFL; ISSN: 1522-8002
PB Neoplasia Press Inc.
DT Journal
LA English
AB EphA2 is a receptor tyrosine kinase and is frequently overexpressed in a wide array of advanced cancers. We demonstrate in the current study that the EphA2 protein is restrictedly expressed in primary glioblastoma multiforme and anaplastic astrocytoma tissues in

comparison to normal brain tissues. To evaluate the possibility of targeting EphA2 in glioma vaccine strategies, we stimulated human leukocyte antigen (HLA) A2+ peripheral blood mononuclear cells (PBMCs) obtained from healthy donors and glioma patients with autologous dendritic cells (DCs) loaded with synthetic EphA2883-891 peptide (TLADFDPRV), which has previously been reported to induce interferon-γ in HLA-A2+ PBMCs. Stimulated PBMCs demonstrated antigen-specific cytotoxic T lymphocyte (CTL) responses as detected by specific lysis of T2 cells loaded with the EphA2883 peptide as well as HLA-A2+ glioma cells, SNB19 and U251, that express EphA2. Furthermore, in vivo immunization of HLA-A2 transgenic HHD mice with the EphA2883-891 peptide resulted in the development of an epitope-specific CTL response in splenocytes, despite the fact that EphA2883-891 is an autoantigen in these mice. Taken together, these data suggest that EphA2883-891 may be an attractive antigen epitope for molecularly targeted glioma vaccines.

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:308529 CAPLUS
DN 140:333599
TI Gene expression profile of human and mouse genes in atopic dermatitis and psoriasis patients and its use for diagnosis, therapy, and drug screening
IN Itoh, Mikito; Ogawa, Kaoru; Shinagawa, Akira; Sudo, Hajime; Ogawa, Hideoki; Ra, Chisei; Mitsuishi, Kouichi
PA Genox Research, Inc., Japan; Juntendo University
SO PCT Int. Appl., 611 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004031386	A1	20040415	WO 2003-JP9808	20030801
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003252326	A1	20040423	AU 2003-252326	20030801
PRAI	JP 2002-229318	A	20020806		
	JP 2003-136543	A	20030514		
	WO 2003-JP9808	W	20030801		

AB This invention provides gene expression profile between a rash site and a no-rash site in a patient with atopic dermatitis or a patient with psoriasis. The invention also provides gene expression profile between a no-rash site in such a disease and a normal subject. Animal models, particularly mouse for those diseases are also claimed. The gene expression profile provided in this invention can be used for diagnosis, therapy, and drug screening for atopic dermatitis and psoriasis.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:837593 CAPLUS
DN 139:322275
TI Peptide T epitopes of the EphA2 antigen for antitumor immunotherapy

IN Kosmatopoulos, Kostas; Alves, Pedro
PA Institut National de la Sante et de la Recherche Medicale INSERM, Fr.; Institut Gustave Roussy
SO Fr. Demande, 22 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2838742	A1	20031024	FR 2002-5048	20020423
	FR 2838742	B1	20040709		
	CA 2482930	AA	20031106	CA 2003-2482930	20030423
	WO 2003091383	A2	20031106	WO 2003-FR1280	20030423
	WO 2003091383	A3	20040401		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003262810	A1	20031110	AU 2003-262810	20030423
	EP 1497417	A2	20050119	EP 2003-740654	20030423
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2006034856	A1	20060216	US 2005-511273	20050627
PRAI	FR 2002-5048	A	20020423		
	WO 2003-FR1280	W	20030423		

AB The invention discloses peptides constituting EphA2 antigen T epitopes, presented by MHC I. The peptides are useful in particular for antitumor immunotherapy.
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:982383 CAPLUS
DN 140:75821
TI EphA2 as Target of Anticancer Immunotherapy: Identification of HLA-A*0201-Restricted Epitopes
AU Alves, Pedro M. S.; Faure, Olivier; Graff-Dubois, Stephanie; Gross, David-Alexandre; Cornet, Sebastien; Chouaib, Salem; Miconnet, Isabelle; Lemonnier, Francois A.; Kosmatopoulos, Kostas
CS INSERM487, Institut Gustave Roussy, Villejuif, Fr.
SO Cancer Research (2003), 63(23), 8476-8480
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
AB EphA2 (Eck) is a tyrosine kinase receptor that is overexpressed in several human cancers such as breast, colon, lung, prostate, gastric carcinoma, and metastatic melanoma but not in nonmalignant counterparts. To validate EphA2 as a tumor antigen recognized by CD8+ T lymphocytes, we used reverse immunol. approach to identify HLA -A*0201-restricted epitopes. Peptides bearing the HLA -A*0201-specific anchor motifs were analyzed for their capacity to bind and stabilize the HLA-A*0201 mols. Two peptides, EphA258 and EphA2550, with a high affinity for HLA-A*0201 were selected. Both peptides were immunogenic in the HLA -A*0201-transgenic HHD mice. Interestingly, peptide-specific murine CTLs cell lines responded to COS-7 cells coexpressing HLA

-A*0201 and EphA2 and to EphA2-pos. human tumor cells of various origin (renal cell, lung, and colon carcinoma and sarcoma). This demonstrates that EphA258 and EphA2550 are naturally processed from endogenous EphA2. In addition, EphA258 and EphA2550 stimulated specific CD8+ T cells from healthy donor peripheral blood mononuclear cells. These T cells recognized EphA2-pos. human tumor cells in an HLA-A*0201-restricted manner. Interestingly, EphA2 -specific CD8+ T cells were detected in the peripheral blood mononuclear cells of prostate cancer patients. These results show for the first time that EphA2 is a tumor rejection antigen and lead us to propose EphA258 and EphA2550 peptides for a broad-spectrum-tumor immunotherapy.

RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:613807 CAPLUS
DN 139:275676
TI Disease Stage Variation in CD4+ and CD8+ T-Cell Reactivity to the Receptor Tyrosine Kinase EphA2 in Patients with Renal Cell Carcinoma
AU Tatsumi, Tomohide; Herrem, Christopher J.; Olson, Walter C.; Finke, James H.; Bukowski, Ronald M.; Kinch, Michael S.; Ranieri, Elena; Storkus, Walter J.
CS Departments of Surgery and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA
SO Cancer Research (2003), 63(15), 4481-4489
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
AB The authors have evaluated CD8+ and CD4+ T-cell responses against a new tumor-associated antigen, the receptor tyrosine kinase EphA2, which is broadly expressed in diverse cancer histologies and is frequently overexpressed in advanced stage/metastatic disease. They report herein that EphA2 is overexpressed in renal cell carcinoma (RCC) cell lines and clin. specimens of RCC, and find that the highest levels of EphA2 are consistently found in the most advanced stages of the disease. The authors identified and synthesized 5 putative HLA class I-binding and 3 class II-binding peptides derived from EphA2 that might serve as targets for immune reactivity. Each peptide induced specific, tumor-reactive CD8+ or CD4+T-cell responses as measured using IFN-γ enzyme-linked immunospot assays. The EphA2 peptides elicited relatively weak responses from CD8+ T cells derived from normal healthy volunteers or from RCC patients with active disease. In marked contrast, immune reactivity to EphA2-derived epitopes was greatly enhanced in CD8+ T cells that had been isolated from patients who were rendered disease-free, after surgery. Furthermore, enzyme-linked immunospot analyses demonstrated prominent EphA2-restricted T-helper 1-type CD4+ T cell activity in patients with early stage disease, whereas T-helper 2-type and T regulatory-type responses predominated in patients with more advanced forms of RCC. Thus, the immune system of cancer patients actively monitors EphA2-derived epitopes, and the magnitude and character of T-cell responses to EphA2 epitopes may convey much-needed predictive information about disease stage and outcome.

RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:937303 CAPLUS
DN 138:20443
TI Endocrine disruptor screening using DNA chips of endocrine disruptor-responsive genes
IN Kondo, Akihiro; Takeda, Takeshi; Mizutani, Shigetoshi; Tsujimoto,

Yoshimasa; Takashima, Ryokichi; Enoki, Yuki; Kato, Ikunoshin
PA Takara Bio Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 386 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2002355079	A2	20021210	JP 2002-69354	20020313
PRAI	JP 2001-73183	A	20010314		
	JP 2001-74993	A	20010315		
	JP 2001-102519	A	20010330		

AB A method and kit for detecting endocrine-disrupting chems. using DNA microarrays are claimed. The method comprises preparing a nucleic acid sample containing mRNAs or cDNAs originating in cells, tissues, or organisms which have been brought into contact with a sample containing the endocrine disruptor. The nucleic acid sample is hybridized with DNA microarrays having genes affected by the endocrine disruptor or DNA fragments originating in these genes have been fixed. The results obtained are then compared with the results obtained with the control sample to select the gene affected by the endocrine disruptor. Genes whose expression is altered by tri-Bu tin, 4-octaphenol, 4-nonylphenol, di-N-Bu phthalate, dichlorohexyl phthalate, octachlorostyrene, benzophenone, diethylhexyl phthalate, diethylstilbestrol (DES), and 17-β estradiol (E2), were found in mice by DNA chip anal.

=> display history
ENTER (BRIEF), FULL, OR NOFILE:full
ENTER (L1-), L#, OR ?:l1

(FILE 'CAPLUS, BIOENG, BIOTECHNO, BIOTECHDS, ESBIOBASE' ENTERED AT 15:00:56 ON 06 OCT 2006)
L1 9390 SEA ABB=ON PLU=ON (T CELL EPITOPE) OR (T EPITOPE)

FILE HOME

FILE CAPLUS

FILE COVERS 1907 - 6 Oct 2006 VOL 145 ISS 16
FILE LAST UPDATED: 5 Oct 2006 (20061005/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

FILE BIOENG
FILE LAST UPDATED: 16 AUG 2006 <20060816/UP>
FILE COVERS 1982 TO DATE

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN

THE BASIC INDEX <<<

FILE BIOTECHNO
FILE LAST UPDATED: 7 JAN 2004 <20040107/UP>
FILE COVERS 1980 TO 2003.

>>> BIOTECHNO IS NO LONGER BEING UPDATED AS OF 2004 <<<

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN /CT AND BASIC INDEX <<<

FILE BIOTECHDS
FILE LAST UPDATED: 4 OCT 2006 <20061004/UP>
FILE COVERS 1982 TO DATE

>>> USE OF THIS FILE IS LIMITED TO BIOTECH SUBSCRIBERS <<<

FILE ESBIOBASE
FILE LAST UPDATED: 3 OCT 2006 <20061003/UP>
FILE COVERS 1994 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN /CC, /ORGN, AND /ST <<<